Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Renal Insufficiency 2Multiple Myeloma 2Kidney Failure, Chronic 2Virus Diseases 1Kidney Diseases 1Graft vs Host Disease 1Epstein-Barr Virus Infections 1

Interventions

Rituximab 4Valganciclovir 2Valacyclovir 2Carboplatin 2Acyclovir 2valomaciclovir 1threonic acid 1otelixizumab 1cc-486 1Zidovudine 1Vincristine 1Vaccines 1Tomography, X-Ray Computed 1Prednisone 1Polymerase Chain Reaction 1Methotrexate 1Matrix-M 1Magnesium Sulfate 1MVA vaccine 1Leucovorin 1Kidney Transplantation 1Interferons 1In Situ Hybridization 1Immunohistochemistry 1Granulocyte Colony-Stimulating Factor 1Gene-Eden-VIR 1Gastrectomy 1Flow Cytometry 1Filgrastim 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Epstein-Barr Virus Infections × Kidney Transplantation × Clear all
NCT01136395 2019-10-08

Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation

University of Giessen

Phase 2 Completed
85 enrolled

Virus Diseases, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡